Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

20 sept. 2016 08h00 HE | Source: Lipocine, Inc.

Lipocine to Present at 2016 Ladenburg Thalmann Healthcare Conference

SALT LAKE CITY, Sept. 20, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
09 août 2016 08h00 HE | Source: Lipocine, Inc.

Lipocine Announces Financial and Operational Results for the Second Quarter of 2016

SALT LAKE CITY, Aug. 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended June 30,...
04 août 2016 08h00 HE | Source: Lipocine, Inc.

Lipocine to Present at 36th Annual Canaccord Genuity Growth Conference

SALT LAKE CITY, Aug. 04, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown, Executive...
29 juin 2016 06h55 HE | Source: Lipocine, Inc.

Lipocine Receives Complete Response Letter (CRL) for LPCN 1021 From U.S. Food and Drug Administration

SALT LAKE CITY, June 29, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has received a Complete Response Letter (“CRL”) from...
27 juin 2016 08h00 HE | Source: Lipocine, Inc.

Lipocine Added to Russell 3000 and Russell Global Indexes

SALT LAKE CITY, June 27, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that it has been added to the Russell 3000® and Russell Global®...
09 mai 2016 16h00 HE | Source: Lipocine Inc.

Lipocine Announces Financial and Operational Results for the First Quarter of 2016

SALT LAKE CITY, May 09, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced financial and operational results for the quarter ended March 31,...
02 mai 2016 08h00 HE | Source: Lipocine Inc.

Lipocine Announces the Presentation of Clinical Data for Oral Testosterone Replacement Therapy Product Candidate TLANDO™ (“LPCN 1021”) at the 2016 American Urological Association Annual Meeting

SALT LAKE CITY, May 02, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for lead candidate TLANDO™ (“LPCN 1021”),...
06 avr. 2016 13h58 HE | Source: Lipocine Inc.

Lipocine to Present at 15th Annual Needham & Company Healthcare Conference

SALT LAKE CITY, April 06, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that Mahesh Patel, President and CEO, and Morgan Brown,...
28 mars 2016 08h30 HE | Source: Lipocine Inc.

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at the American Society of Andrology 41st Annual Conference

SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...
28 mars 2016 08h30 HE | Source: Lipocine Inc.

Lipocine Announces the Presentation of Clinical Data for LPCN 1021, Its Oral Testosterone Replacement Therapy Product Candidate, at ENDO 2016

SALT LAKE CITY, March 28, 2016 (GLOBE NEWSWIRE) -- Lipocine Inc. (NASDAQ:LPCN), a specialty pharmaceutical company, today announced that clinical data for LPCN 1021, an oral testosterone...

Page précédente

Page suivante